Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
31/10 10:05
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent, there's almost always a dispute about exactly who is the rightful owner of the re...